Insider Transactions in Q1 2022 at Sierra Oncology, Inc. (SRRA)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
SELL
Open market or private sale
|
Direct |
100
-100.0%
|
$3,700
$37.05 P/Share
|
|
Mar 18
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+50.0%
|
$1,200
$12.05 P/Share
|
|
Mar 17
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
SELL
Open market or private sale
|
Direct |
3,453
-100.0%
|
$127,761
$37.06 P/Share
|
|
Mar 17
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,453
+50.0%
|
$41,436
$12.05 P/Share
|
|
Mar 04
2022
|
Mary Christina Thomson General Counsel |
SELL
Open market or private sale
|
Direct |
2,000
-100.0%
|
$60,000
$30.6 P/Share
|
|
Mar 04
2022
|
Mary Christina Thomson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$26,000
$13.04 P/Share
|
|
Feb 07
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$320,000
$32.32 P/Share
|
|
Feb 07
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$120,000
$12.05 P/Share
|
|
Feb 04
2022
|
Mary Christina Thomson General Counsel |
SELL
Open market or private sale
|
Direct |
2,000
-100.0%
|
$58,000
$29.78 P/Share
|
|
Feb 04
2022
|
Mary Christina Thomson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$26,000
$13.04 P/Share
|
|
Feb 02
2022
|
Joshua Richardson Director |
BUY
Open market or private purchase
|
Indirect |
175,000
+50.0%
|
$4,725,000
$27.0 P/Share
|
|
Feb 02
2022
|
Longitude Capital Partners Iii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
175,000
+50.0%
|
$4,725,000
$27.0 P/Share
|
|
Jan 31
2022
|
Andrew Sinclair Director |
BUY
Open market or private purchase
|
Indirect |
150,000
+10.25%
|
$4,050,000
$27.0 P/Share
|
|
Jan 31
2022
|
Abingworth LLP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
150,000
+10.25%
|
$4,050,000
$27.0 P/Share
|
|
Jan 31
2022
|
Gaurav Aggarwal Director |
BUY
Open market or private purchase
|
Indirect |
800,000
+22.63%
|
$21,600,000
$27.0 P/Share
|
|
Jan 31
2022
|
Vivo Opportunity, LLC Director |
BUY
Open market or private purchase
|
Indirect |
800,000
+22.63%
|
$21,600,000
$27.0 P/Share
|
|
Jan 28
2022
|
Andrew Sinclair Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
287,471
+19.8%
|
$3,737,123
$13.2 P/Share
|
|
Jan 28
2022
|
Abingworth LLP > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
287,471
+19.8%
|
$3,737,123
$13.2 P/Share
|
|
Jan 26
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$135,000
$27.05 P/Share
|
|
Jan 26
2022
|
William D. Turner Chief Reg & Tech Ops Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$60,000
$12.05 P/Share
|
|
Jan 26
2022
|
Mary Christina Thomson General Counsel |
SELL
Open market or private sale
|
Direct |
2,000
-100.0%
|
$58,000
$29.0 P/Share
|
|
Jan 26
2022
|
Mary Christina Thomson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$26,000
$13.04 P/Share
|
|
Jan 26
2022
|
Gaurav Aggarwal Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
480,277
+19.88%
|
$6,243,601
$13.2 P/Share
|
|
Jan 26
2022
|
Vivo Opportunity, LLC Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
612,437
+17.71%
|
$7,961,681
$13.2 P/Share
|
|
Jan 26
2022
|
Mona Ashiya Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
487,450
+19.88%
|
$6,336,850
$13.2 P/Share
|
|
Jan 26
2022
|
Orbimed Advisors LLC Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
487,450
+19.88%
|
$6,336,850
$13.2 P/Share
|
|
Jan 25
2022
|
Joshua Richardson Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
487,451
+19.88%
|
$6,336,863
$13.2 P/Share
|
|
Jan 25
2022
|
Longitude Capital Partners Iii, LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
487,451
+19.88%
|
$6,336,863
$13.2 P/Share
|